多西紫杉醇联合吡柔比星新辅助化疗治疗局部晚期乳腺癌临床疗效  

Combination of docetaxel and pirarubicin in the neoadjuvant chemotherapy of locally advanced breast cancer

作　　者：吴天峰[1] 范春香[1] 郗蕊[1] 

机构地区：[1]河南省商丘市第一人民医院肿瘤科,商丘476100

出　　处：《临床医学》2011年第12期12-14,共3页Clinical Medicine

摘　　要：目的观察多西紫杉醇联合吡柔比星在新辅助化疗治疗晚期乳腺癌的疗效及不良反应。方法 45例原发晚期乳腺癌患者采用多西紫杉醇联合吡柔比星方案,术前化疗2～4个周期,术后完成规定化疗,观察近期疗效及不良反应。结果新辅助化疗临床疗效总有效率为88%,其中3例病理为完全缓解,主要不良反应为呕吐,粒细胞减少及脱发。结论多西紫杉醇联合吡柔比星新辅助化疗治疗晚期乳腺癌疗效显著,不良反应可耐受,是新辅助化疗治疗晚期乳腺癌的有效方案之一。Objective To observe the early response and toxicity of neoadjuvant chemotherapy with ocetaxel and priubicin in patients with advanced breast cancer.Methods Totally 45 patients with operable stage breast cancer were treated with neoadjuvant chemotherapy,the regiments of neoadjuvant chemotherapy were ocetaxel combined with pirarubicin（THP）.All patients received 2-4 cycles of neoadjuvant chemotherapy,clinical response of neoadjuvant chemotherapy was evaluated in all patients.Results The clinical response of neoadjuvant chemotherapy rate was 88%,the most common toxic effects were nausea/vomiting（Ⅱ,Ⅳgrade）and hematologic toxicity.Leukopenia was the most frequent toxicity.Conclusion Combination chemotherapy of ocetaxel and pirarubicin（THP）is well tolerated and effective in the treatment of neoadjuvant chemotherapy of locally advanced breast cancer.

关 键 词：乳腺癌 新辅助化疗 多西紫杉醇 吡柔吡星 

分 类 号：R737.9[医药卫生—肿瘤]